EyePoint (EYPT) is back in focus after topline data from its pivotal LUGANO Phase 3 trial of DURAVYU in wet age related macular degeneration, raising fresh questions and interest around the stock.

The LUGANO readout has sharply reset expectations around EyePoint, with the share price down about 73% year to date and the 1 year total shareholder return declining about 57%. This points to fading momentum as investors reassess both execution risk and future growth potential.

If this kind of clinical trial swing has you reassessing your watchlist, it can be useful to compare other ophthalmology and biotech names using a healthcare focused screen, including 40 healthcare AI stocks.

EyePoint now trades far below the average analyst price target, yet the LUGANO miss and widening losses show why the market has pulled back hard. Is that markdown an overreaction to a messy dataset, or does it reflect justified caution?

Most Popular Narrative: 88% Undervalued

At a last close of $4.87 versus a narrative fair value of about $40.54, EyePoint is framed as heavily discounted, with that gap resting on some bold assumptions.

Analysts are assuming EyePoint's revenue will grow by 259.6% annually over the next 3 years. Analysts are not forecasting that EyePoint will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate EyePoint's profit margin will increase from 3567.1% to the average AU Pharmaceuticals industry of 19.7% in 3 years.

Want to see what has to go right for that valuation gap to close? The narrative leans on rapid revenue expansion, margin rebuilding, and a rich future earnings multiple. Curious which specific milestones and forecast ranges sit underneath those assumptions?

Result: Fair Value of $40.54 (UNDERVALUED)

However, the EyePoint story still hinges heavily on DURAVYU approvals and commercialization. Ongoing losses and minimal current revenue leave little buffer if timelines slip.

Next Steps

With EyePoint's story pulling in different directions, it makes sense to move quickly and review the underlying data yourself. To see how the balance of concerns and potential upsides stacks up, start with the 1 key reward and 5 important warning signs.

Looking for more investment ideas beyond EyePoint?

If EyePoint has sharpened your focus on stock selection, do not stop here. Use the Simply Wall Street Screener to spot fresh ideas before others notice.

• Target potential mispricings by scanning for companies that look attractively valued using the 53 high quality undervalued stocks.
• Prioritise resilience by zeroing in on businesses with strong finances through the solid balance sheet and fundamentals stocks screener (50 results).
• Hunt for early stage standouts that the market may be overlooking with the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.